President Donald Trump signed an executive order aimed at reducing pharmaceutical drug prices for Americans. The directive, which the president labeled as a means to create fairness in the healthcare system, seeks to eliminate intermediaries that contribute to high drug costs. Trump asserted that the United States will no longer subsidize drug prices for other nations, particularly in the European Union, and introduced a policy called "Most Favored Nation." This policy is intended to ensure that Americans pay the lowest prices available globally, rather than significantly higher costs as has been the norm.
Health and Human Services Secretary Robert F. Kennedy Jr. supported the initiative, suggesting that if other countries increased their drug prices by just 20%, it could lead to substantial savings in the U.S. The administration anticipates that the new executive order could reduce drug prices by up to 80%. During the press conference, White House Press Secretary Karoline Leavitt emphasized that previous administrations had only discussed drug pricing issues, while Trump is taking decisive action.
This executive order follows another directive signed by Trump on May 5, which aims to alleviate regulatory burdens associated with the domestic production of essential medicines. The order highlights concerns regarding the lengthy timelines required to establish pharmaceutical manufacturing facilities in the U.S., which can take between five to ten years due to extensive federal, state, and local regulations.
In summary, the executive order represents a significant policy shift intended to lower drug prices and streamline pharmaceutical manufacturing in the United States, with the administration asserting that these changes will ultimately benefit American consumers.